Prospective Phase 2 Trial of High-Dose Gemcitabine/Busulfan/Melphalan (Gem/Bu/Mel) with Autologous Stem Cell Transplant (ASCT) in Hodgkin's Lymphoma Patients at High Risk of Post-Transplant Recurrence—Comparison with a Concurrent Matched Cohort

Subjects

Subjects :

Oncology
Transplantation
medicine.medical_specialty
business.industry
Hematology
Hodgkin's lymphoma
medicine.disease
Gemcitabine
Post transplant
03 medical and health sciences
0302 clinical medicine
Matched cohort
Busulfan/Melphalan
030220 oncology & carcinogenesis
Internal medicine
Medicine
Stem cell
business
030215 immunology
medicine.drug

Details

ISSN :

10838791

Volume :

23

Database :

OpenAIRE

Journal :

Biology of Blood and Marrow Transplantation

Accession number :

edsair.doi...........8733dedae38befcdd9d2391520c7b981

Full Text :

https://doi.org/10.1016/j.bbmt.2016.12.432